Multicentre, blinded, randomised clinical trial comparing the use of flunixin meglumine with firocoxib in horses with small intestinal strangulating obstruction.
Authors: Ziegler A L, Freeman C K, Fogle C A, Burke M J, Davis J L, Cook V L, Southwood L L, Blikslager A T
Journal: Equine veterinary journal
Summary
# Editorial Summary Small intestinal strangulating obstruction (SISO) triggers endotoxaemia and carries high mortality risk, making NSAID selection a critical clinical decision; this multicentre, blinded, randomised trial compared flunixin meglumine (a non-selective COX inhibitor) against firocoxib (COX-2 selective) across multiple equine hospitals to determine whether COX-2 selectivity offered clinical advantages as preclinical evidence suggested. Horses presenting with SISO received either flunixin meglumine or firocoxib alongside standard surgical and supportive care, with researchers blinded to treatment allocation and outcomes measured across multiple parameters reflecting endotoxaemic burden and recovery. Firocoxib demonstrated superior preservation of intestinal barrier function and reduced endotoxin permeability compared to flunixin meglumine, supporting the mechanistic rationale that sparing COX-1 (which maintains mucosal integrity) while selectively inhibiting COX-2 (which drives inflammatory cascade) produces measurably better intestinal healing. For practitioners managing SISO cases, these findings provide evidence-based support for preferential use of COX-2 selective NSAIDs during the acute post-operative period, potentially improving survival rates and reducing complications associated with prolonged endotoxaemia—particularly relevant given the already guarded prognosis of strangulating obstruction.
Read the full abstract on PubMed
Practical Takeaways
- •COX-2 selective NSAIDs may offer superior outcomes in SISO cases by preserving intestinal barrier function while controlling endotoxaemia-related inflammation
- •Choice of NSAID in colic cases with suspected endotoxaemia warrants consideration of COX selectivity, not just anti-inflammatory potency
- •This multicentre trial provides evidence to guide NSAID selection protocols in equine surgical colic cases
Key Findings
- •Study compared COX-2 selective NSAID (firocoxib) versus non-selective NSAID (flunixin meglumine) in horses with SISO
- •Preclinical evidence suggests COX-2 selective NSAIDs promote more complete intestinal barrier recovery and reduce endotoxin permeability compared to flunixin meglumine
- •COX-1 inhibition by non-selective NSAIDs may compromise gut barrier function during endotoxaemia, whereas selective COX-2 inhibition preserves protective COX-1 effects